SecBot SecBot
SECBOTREPLAY Home › Report › RGNX

RGNX · REGENXBIO announced the first patient dosing in the Phase IIb/III…

REGENXBIO Inc. · 8-K filed Jun 29, 2026 at 07:15 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 29, 2026 at 07:15 ET

REGENXBIO announced the first patient dosing in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (sura-vec) in diabetic retinopathy using suprachoroidal delivery. This triggered a $100 million milestone payment from AbbVie, expected in July 2026. The event de-risks the program's regulatory path and provides a significant non-dilutive cash infusion for a company with a $677 million market cap.

  • First patient dosed in Phase IIb/III NAAVIGATE trial of surabgene lomparvovec in diabetic retinopathy (suprachoroidal delivery)
  • $100 million milestone payment earned from AbbVie, expected in July 2026
  • NAAVIGATE trial to enroll approximately 135 participants in the US; primary endpoint is >2-step DRSS improvement at one year
  • Two-and-a-half year data from ALTITUDE trial and five-year data from Phase I/IIa subretinal wet AMD study to be presented at ASRS July 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access